SLN365 / Silence Therap - LARVOL DELTA

Preclinical programs include SLN365 (GPR146) for familial hypercholesterolemia, targeting an IND in 2H 2027, and SLN098 (INHBE) for obesity and metabolic disease, with ~90% target knockdown in primates and a potential IND by 2027 year‑end (StockTitan.net)

IND • Familial Hypercholesterolemia • Obesity

Anticipated 2026 Milestones (Businesswire) - "Additional preclinical data for SLN365 (GPR146) in second quarter of 2026; Additional preclinical data for SLN098 (INHBE) in second quarter of 2026."

Preclinical • Homozygous Familial Hypercholesterolemia • Obesity